GlaxoSmithKline (GSK) announced that it has sold two thrombosis brands and a French plant to South African company Aspen for 700 million. "GSK today announced it has reached agreement to sell its thrombosis brands, Arixtra and Fraxiparine, and the Notre-Dame de Bondeville manufacturing site to The Aspen Group," said a statement. "The agreement is a further example of GSK's commitment to increase focus on products with the most growth potential," it ...You have just read an article categorized health
titled GSK Sells Thrombosis Brands to Aspen.
Written by:
editor - Tuesday, October 1, 2013
There are currently no comments for "GSK Sells Thrombosis Brands to Aspen"
Post a Comment